The University of Bologna is a university in Bologna, Italy, founded in 1088. As of 2013 the University's crest carries the motto Alma mater studiorum and the date A.D. 1088. The University has about 85,000 students in its 23 schools. It has branch centres in Imola, Ravenna, Forlì, Cesena and Rimini and a branch center abroad in Buenos Aires. It also has a school of excellence named Collegio Superiore di Bologna. It is recognised as the oldest university in continuous operation, considering that it was the first to use the term universitas for the corporations of students and masters which came to define the institution.The publisher of the University of Bologna is Bononia University Press S.p.A . Wikipedia.
BRESMEDICAL PTY Ltd and University of Bologna | Date: 2015-03-27
A computer-implemented method for surgical planning and/or surgical navigation. A surgical navigation and/or planning system is also provided, that can include aspects of the computer-implemented method, which allows virtual implant planning, and receives real-time data from a tracker. The system can also include one or more hardware components which allow real-time imaging of one or more surgical instruments onto, relative to or over a patients anatomy. The system and computer-implemented method improve the precision and safety of image based surgery, for example precision placement of bone implants during surgery. A software application is used to manage drill-guide assisted surgery and image-guided surgery. This provides a method and system for Computer Assisted Surgery (CAS) which improves accuracy and safety of a variety of surgical procedures.
Italian Institute of Technology and University of Bologna | Date: 2015-06-12
The present invention relates to Compounds of Formula (I) and pharmaceutical compositions containing the same. It further relates to their use in the prevention or treatment of central nervous system diseases or disorders, in particular, cognitive, neurodegenerative or neuronal diseases or disorders.
University of Bologna and Glassup S.R.L. | Date: 2015-03-27
The invention describes augmented reality glasses (1) for medical applications configured to be worn by a user, comprising a frame (15) that supports a glasses lens (2a, 2b), wherein the frame (15) comprises an RGB lighting system comprising RGB-emitting devices (16a, 16b, 16c) configured to emit light beams (B1, B2, B3); first optical systems (17a, 17b, 17c) configured to collimate at least partially said beams (B1, B2, B3) into collimated beams (B1c; B2c; B3c); wherein the frame (15) further comprises a display (3) configured to be illuminated by the RGB lighting system (16) by means of the collimated beams (B1c; B2c; B3c); to receive first images (I) from a first processing unit (10); to emit the first images (I) as second images (IE1) towards the glasses lens (2a, 2b), wherein the lens (2a, 2b) is configured to reflect the second images (IE1) coming from the display (3) as images projected (IP) towards an internal zone (51) of the glasses corresponding to an eye position zone of the user who is wearing the glasses in a configuration for use of the glasses. The invention moreover describes an augmented reality system for medical applications on a user comprising the augmented reality glasses (1) of the invention, biomedical instrumentation (100) configured to detect biomedical and/or therapeutic and/or diagnostic data of a user and to generate first data (D1) representative of operational parameters (OP_S) associated with the user, transmitting means (101) configured to transmit the first data (D1) to the glasses (1); wherein the glasses (1) comprise a first processing unit (10) equipped with a receiving module (102) configured to receive the first data (D1) comprising the operational parameters (OP_S) associated with the user.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: SC1-PM-09-2016 | Award Amount: 6.19M | Year: 2017
Chronic aortic aneurysms are permanent and localized dilations of the aorta that remain asymptomatic for long periods of time but continue to increase in diameter before they eventually rupture. Left untreated, the patients prognosis is dismal, since the internal bleeding of the rupture brings about sudden death. Although successful treatment cures the disease, the risky procedures can result in paraplegia from spinal cord ischaemia or even death, particularly for aneurysms extending from the thoracic to the abdominal aorta and thus involving many segmental arteries to the spinal cord, i.e. thoracoabdominal aortic aneurysms of Crawford type II. Although various strategies have achieved a remarkable decrease in the incidence of paraplegia, it is still no less than 10 to 20%. However, it has been found that the deliberate occlusion of the segmental arteries to the paraspinous collateral network finally supplying the spinal cord does not increase rates of permanent paraplegia. A therapeutic option, minimally invasive segmental artery coil embolization has been devised which proceeds in a staged way to occlude groups of arteries under highly controlled conditions after which time must be allowed for arteriogenesis to build a robust collateral blood supply. PAPA-ARTiS is a phase II trial to demonstrate that a staged treatment approach can reduce paraplegia and mortality dramatically. It can be expected to have both a dramatic impact on the individual patients quality of life if saved from a wheelchair, and also upon financial systems through savings in; 1) lower costs in EU health care; 2) lower pay-outs in disability insurance (est. at 500k in Year 1), and; 3) loss of economic output from unemployment. Approx. 2500 patients a year in Europe undergo these high risk operations with a cumulative paraplegia rate of over 15%; therefore >100M per year in costs can be avoided and significantly more considering the expected elimination of type II endoleaks.
Agency: European Commission | Branch: H2020 | Program: SGA-RIA | Phase: FETFLAGSHIP | Award Amount: 89.00M | Year: 2016
This project is the second in the series of EC-financed parts of the Graphene Flagship. The Graphene Flagship is a 10 year research and innovation endeavour with a total project cost of 1,000,000,000 euros, funded jointly by the European Commission and member states and associated countries. The first part of the Flagship was a 30-month Collaborative Project, Coordination and Support Action (CP-CSA) under the 7th framework program (2013-2016), while this and the following parts are implemented as Core Projects under the Horizon 2020 framework. The mission of the Graphene Flagship is to take graphene and related layered materials from a state of raw potential to a point where they can revolutionise multiple industries. This will bring a new dimension to future technology a faster, thinner, stronger, flexible, and broadband revolution. Our program will put Europe firmly at the heart of the process, with a manifold return on the EU investment, both in terms of technological innovation and economic growth. To realise this vision, we have brought together a larger European consortium with about 150 partners in 23 countries. The partners represent academia, research institutes and industries, which work closely together in 15 technical work packages and five supporting work packages covering the entire value chain from materials to components and systems. As time progresses, the centre of gravity of the Flagship moves towards applications, which is reflected in the increasing importance of the higher - system - levels of the value chain. In this first core project the main focus is on components and initial system level tasks. The first core project is divided into 4 divisions, which in turn comprise 3 to 5 work packages on related topics. A fifth, external division acts as a link to the parts of the Flagship that are funded by the member states and associated countries, or by other funding sources. This creates a collaborative framework for the entire Flagship.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: SC1-PM-09-2016 | Award Amount: 6.00M | Year: 2017
Liver cirrhosis is a very common chronic disease and one of the leading causes of death in European. Moreover, cirrhosis has a marked impact in patients quality of life and represents a major burden for health systems. Treatment of cirrhosis is currently based on symptomatic management of complications and has not changed substantially in the last 20 years. There is an unmet need for therapies that target the pathobiology of cirrhosis. The objective of LIVERHOPE project is to evaluate a novel therapeutic strategy for patients with cirrhosis based on a combination of rifaximin and simvastatin, targeting the main pathophysiological mechanisms of disease progression , namely the impairment in the gut-liver axis and the persistent hepatic and systemic inflammatory response. This dual therapeutic approach is supported by preclinical data showing excellent and very promising results. We will perform two randomized double-blind trials to investigate safety, tolerability and efficacy of combination of simvastatin plus rifaximin in patients with decompensated cirrhosis in 5 EU countries (285 patients will be enrolled in two trials in DE, ES, FR, IT, UK). The expected impact is to halt progression to acute-on-chronic liver failure, the main cause of death, to decrease complications of the disease, to reduce hospital readmissions, to improve cost-effectiveness of therapy. Our final aim is to improve patients quality-of-life and increase survival as patients care is the core of LIVERHOPE. Within the project we will also investigate biomarkers of response to treatment and disease progression that can be useful in clinical practice for improving the treatment of patients. We will invest our effort also in communication and dissemination activities for increasing awareness about chronic liver diseases in European countries so that preventive measures can be established to decrease the burden of cirrhosis and reduce social stigmatization of patients with chronic liver diseases.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: FETPROACT-01-2016 | Award Amount: 5.99M | Year: 2017
Guaranteed numerical precision of each elementary step in a complex computation has been the mainstay of traditional computing systems for many years. This era, fueled by Moores law and the constant exponential improvement in computing efficiency, is at its twilight: from tiny nodes of the Internet-of-Things, to large HPC computing centers, sub-picoJoule/operation energy efficiency is essential for practical realizations. To overcome the power wall, a shift from traditional computing paradigms is now mandatory. OPRECOMP aims at demolishing the ultra-conservative precise computing abstraction and replacing it with a more flexible and efficient one, namely transprecision computing. OPRECOMP will investigate the theoretical and practical understanding of the energy efficiency boost obtainable when accuracy requirements on data being processed, stored and communicated can be lifted for intermediate calculations. While approximate computing approaches have been used before, in OPRECOMP for the first time ever, a complete framework for transprecision computing, covering devices, circuits, software tools, and algorithms, along with the mathematical theory and physical foundations of the ideas will be developed that not only will provide error bounds with respect to full precision results, but also will enable major energy efficiency improvements even when there is no freedom to relax end-to-end application quality-of-results. The mission of OPRECOMP is to demonstrate using physical demonstrators that this idea holds in a huge range of application scenarios in the domains of IoT, Big Data Analytics, Deep Learning, and HPC simulations: from the sub-milliWatt to the MegaWatt range, spanning nine orders of magnitude. In view of industrial exploitation, we will prove the quality and reliability and demonstrate that transprecision computing is the way to think about future systems.